Members and friends of Virginia Bio,
Access to capital is one of the most important and pressing needs of bioscience innovation companies. The need for capital starts even before the moment of creation of the company, and continues and evolves throughout all stages of a company’s life cycle.
Virginia Bio is continually seeking ways to help our member companies access capital, and in the year ahead we will provide increased emphasis, and new programs and projects.
To jump start this effort, Virginia Bio recently entered into a one year agreement with CB Insights to provide access for select members to CB Insight’s proprietary comprehensive database of private investment data on current and historic deals and investors.
CB Insights is a national Science Foundation-backed data and technology company that exclusively focuses on private company financing and exit information. The database tracks any private company that has received financing including government grants angel investment, VC, growth equity, or had an exit via M&A, an IPO or other, and captures extensive information on the financings and the investors.
A handful of Virginia Bio member companies and investment advisors who helped us evaluate the database service were impressed that this will be a valuable tool. It will help our startup, early stage and growing companies analyze industry trends, identify target investors and acquirers, conduct reverse due diligence on investors prior to meeting them, understand comparable transactions and competitors, and track and research relevant life science and health care deals.
In addition to this new service, in January we’ll continue to build on our support of companies during JP Morgan week, with a second private meeting room and a much expanded networking reception Sunday night.
Please let me and members of our Board know additional ideas for supporting our companies’ efforts to gain access to the capital they need to thrive.